Gemini 2 5 0 4

• Gemini 2 5 0 4 Speed
• Gemini 2 5 0 4 0 2n
• Gemini 2 5 0 4 Mg

The all new Gemini 2-1.2K is a solid state 1200W CW output Linear Amplifier for 144-148Mhz. The Gemini 2-1.2K has been designed from the start with high duty cycle usage in mind. The core of the amplifier is dominated by a 7.5Kg aluminium heatsink cooled by three temperature controlled fans. The Gemini-2 is a highly flexible solution for scribing and cutting cable shields, in particular tinned micro-coax and aluminized foils. Particular features of this model include: A large 5″ x 7″ (127 mm x 178 mm) working area for multiple wire processing and high productivity. Vedolizumab, as compared with placebo, was associated with a higher rate of serious adverse events (24.4% vs. 15.3%), infections (44.1% vs. 40.2%), and serious infections (5.5% vs. 3.0%).CONCLUSIONS: Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100. On 19 January 1965, the Gemini 2 suborbital test mission was launched, with the second prototype Gemini capsule. 3 4 In March 1965, NASA approved the transfer of the Gemini 2 capsule to the USAF for modification into the first prototype of the Gemini B capsule.

Gemini 2 (Gemini-Titan 2; GT-2)^[2] was the second spaceflight of the American human spaceflight program Project Gemini, and was launched and recovered on January 19, 1965. Gemini 2, like Gemini 1, was an unmanned mission intended as a test flight of the Gemini spacecraft. Unlike Gemini 1, which was placed into orbit, Gemini 2 made a suborbital flight, primarily intended to test the spacecraft's heat shield. It was launched on a Titan II GLV rocket. The spacecraft used for the Gemini 2 mission was later refurbished into the Gemini B configuration, and was subsequently launched on another suborbital flight, along with OPS 0855, as a test for the US Air Force Manned Orbital Laboratory. Gemini spacecraft no. 2 was the first craft to make more than one spaceflight since the X-15, and the only one until Space Shuttle Columbia flew its second mission in 1981. Noteplan 1 6 20 – daily planning for professionals.

Mission history[edit]

GLV[edit]

The Titan II/Gemini launch vehicle was dismantled to protect it from two hurricanes in August and September 1964. The second stage of the vehicle was taken down and stored in a hangar on August 26, 1964 in preparation for Hurricane Cleo, and the entire launch vehicle was subsequently dismantled and removed from Cape Kennedy Air Force Station's Launch Complex19 in early September before Hurricane Dora passed over Cape Kennedy on September 9. The Gemini launch vehicle was erected for the final time on 12 September 1964.

Many ground tests were carried out on the Gemini 2 and Titan rocket in November 1964. On November 24, Gemini-Titan (GT) 2 successfully completed the Wet Mock Simulated Launch, a full-scale countdown exercise which included propellant loading. Procedures for flight crew suiting and spacecraft ingress and egress were practiced during simulated launch. The prime flight crew for Gemini 3 donned pressure suits and full biomedical instrumentation, assisted by their backup crew and the space suit bioinstrumentation and aeromedical personnel who would participate in the GT-3 launch operation. As a result of this practice operation, it was established that all physical examinations, bioinstrumentation sensor attachment, and suit donning would be done in the pilot ready room at Launch Complex 16.

Gemini 2 had been scheduled for launch on December 9, 1964. On that date, the countdown reached zero and the first stage engines were ignited. The launch vehicle's Malfunction Detection System detected technical problems due to a loss of hydraulic pressure and shut down the engines about one second after ignition.

On the second launch attempt on January 19, 1965, Gemini 2 lifted off from Launch Complex 19 at Cape Kennedy at 9:03:59 a.m. EST (14:03:59.861 UTC).

Shortly after launch the Mission Control Center suffered a power outage. Control of the mission was transferred to a tracking ship. The outage was later traced to an overload of the electrical system from the network television equipment used to cover the launch.^[3]

Gemini 2 flew a ballistic suborbital arc over the Atlantic Ocean reaching a maximum altitude of 92.4 nautical miles (171.1 km). The spacecraft was run by an onboard automatic sequencer. At 6 minutes 54 seconds after launch, retrorockets were fired. The spacecraft landed 1,847.9 nautical miles (3,422 km) downrange from the launch pad. The flight lasted 18 minutes 16 seconds. The landing was 14 nautical miles (26 km) short of the planned impact point, and 45 nautical miles (83 km) from the recovery aircraft carrier, USS Lake Champlain. The spacecraft was brought aboard the carrier at 15:52 UT (10:52 a.m. EST). Most goals were achieved, except the fuel cells had failed before liftoff and were turned off. The spacecraft cooling system temperature also was found to be too high. The Gemini 2 spacecraft was in excellent condition. Its heat shield and retrorockets functioned as expected. The Gemini 2 mission was supported by 6,562 United States Department of Defense personnel, 67 aircraft, and 16 ships.

Gemini 2 had flight instrumentation pallets installed in the crew cabin, similar to those in Gemini 1.

MOL[edit]

The Gemini 2 reentry module was refurbished and flown again on November 3, 1966 in a test flight for the United States Air ForceManned Orbiting Laboratory program. It was launched on a Titan IIIC rocket on a 33-minute suborbital flight from LC-40 at Cape Kennedy. It is the only Gemini spacecraft to have flown with U.S. Air Force insignia, but there is an unflown Gemini B spacecraft in USAF markings on display at the National Museum of the United States Air Force at Wright-Patterson Air Force Base in Dayton, Ohio.

Gallery[edit]

• SC2 is launched for a second time aboard a Titan 3C in November 1966, on a suborbital test flight for the USAF MOL project.

• Gemini 2 instrument pallets (NASA)

• Gemini 2 spacecraft on display at the Air Force Space and Missile Museum, Cape Canaveral Air Force Station, Florida.

• Gemini 2 spacecraft on display at the Air Force Space and Missile Museum, Cape Canaveral.

See also[edit]

References[edit]

This article incorporates public domain material from websites or documents of the National Aeronautics and Space Administration.

1. ^Hacker, Barton C.; Grimwood, James M. (February 2003) [First published 1977]. 'Table of Contents'. On the Shoulders of Titans: A History of Project Gemini. NASA History Division, Office of Policy and Plans. NASA History Series. Washington, D.C.: NASA. NASA SP-4203. Retrieved September 12, 2013.
2. ^'Gemini 2'. NASA Space Science Data Coordinated Archive (NSSDCA). NASA. 2017. GEMINI2.
3. ^Chris Kraft, Flight, p. 206.

External links[edit]

• The Gemini II Reentry Mission - 1965 - NASA on YouTube
• Gemini II reentry at real speed - HD source on YouTube

Gitftp deploy 2 5 5 download free.

• < Previous
• Next >

Home > Aurora Residents and Fellows > Aurora Gastroenterology Fellows > 14

Title

GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease

Many ground tests were carried out on the Gemini 2 and Titan rocket in November 1964. On November 24, Gemini-Titan (GT) 2 successfully completed the Wet Mock Simulated Launch, a full-scale countdown exercise which included propellant loading. Procedures for flight crew suiting and spacecraft ingress and egress were practiced during simulated launch. The prime flight crew for Gemini 3 donned pressure suits and full biomedical instrumentation, assisted by their backup crew and the space suit bioinstrumentation and aeromedical personnel who would participate in the GT-3 launch operation. As a result of this practice operation, it was established that all physical examinations, bioinstrumentation sensor attachment, and suit donning would be done in the pilot ready room at Launch Complex 16.

Gemini 2 had been scheduled for launch on December 9, 1964. On that date, the countdown reached zero and the first stage engines were ignited. The launch vehicle's Malfunction Detection System detected technical problems due to a loss of hydraulic pressure and shut down the engines about one second after ignition.

On the second launch attempt on January 19, 1965, Gemini 2 lifted off from Launch Complex 19 at Cape Kennedy at 9:03:59 a.m. EST (14:03:59.861 UTC).

Shortly after launch the Mission Control Center suffered a power outage. Control of the mission was transferred to a tracking ship. The outage was later traced to an overload of the electrical system from the network television equipment used to cover the launch.^[3]

Gemini 2 flew a ballistic suborbital arc over the Atlantic Ocean reaching a maximum altitude of 92.4 nautical miles (171.1 km). The spacecraft was run by an onboard automatic sequencer. At 6 minutes 54 seconds after launch, retrorockets were fired. The spacecraft landed 1,847.9 nautical miles (3,422 km) downrange from the launch pad. The flight lasted 18 minutes 16 seconds. The landing was 14 nautical miles (26 km) short of the planned impact point, and 45 nautical miles (83 km) from the recovery aircraft carrier, USS Lake Champlain. The spacecraft was brought aboard the carrier at 15:52 UT (10:52 a.m. EST). Most goals were achieved, except the fuel cells had failed before liftoff and were turned off. The spacecraft cooling system temperature also was found to be too high. The Gemini 2 spacecraft was in excellent condition. Its heat shield and retrorockets functioned as expected. The Gemini 2 mission was supported by 6,562 United States Department of Defense personnel, 67 aircraft, and 16 ships.

Gemini 2 had flight instrumentation pallets installed in the crew cabin, similar to those in Gemini 1.

MOL[edit]

The Gemini 2 reentry module was refurbished and flown again on November 3, 1966 in a test flight for the United States Air ForceManned Orbiting Laboratory program. It was launched on a Titan IIIC rocket on a 33-minute suborbital flight from LC-40 at Cape Kennedy. It is the only Gemini spacecraft to have flown with U.S. Air Force insignia, but there is an unflown Gemini B spacecraft in USAF markings on display at the National Museum of the United States Air Force at Wright-Patterson Air Force Base in Dayton, Ohio.

Gallery[edit]

• SC2 is launched for a second time aboard a Titan 3C in November 1966, on a suborbital test flight for the USAF MOL project.

• Gemini 2 instrument pallets (NASA)

• Gemini 2 spacecraft on display at the Air Force Space and Missile Museum, Cape Canaveral Air Force Station, Florida.

• Gemini 2 spacecraft on display at the Air Force Space and Missile Museum, Cape Canaveral.

See also[edit]

References[edit]

This article incorporates public domain material from websites or documents of the National Aeronautics and Space Administration.

1. ^Hacker, Barton C.; Grimwood, James M. (February 2003) [First published 1977]. 'Table of Contents'. On the Shoulders of Titans: A History of Project Gemini. NASA History Division, Office of Policy and Plans. NASA History Series. Washington, D.C.: NASA. NASA SP-4203. Retrieved September 12, 2013.
2. ^'Gemini 2'. NASA Space Science Data Coordinated Archive (NSSDCA). NASA. 2017. GEMINI2.
3. ^Chris Kraft, Flight, p. 206.

External links[edit]

• The Gemini II Reentry Mission - 1965 - NASA on YouTube
• Gemini II reentry at real speed - HD source on YouTube

Gitftp deploy 2 5 5 download free.

• < Previous
• Next >

Home > Aurora Residents and Fellows > Aurora Gastroenterology Fellows > 14

Title

GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease

Recommended Citation

Faculty, Aurora Gastroenterology; Sandborn, W.; Feagan, B.; Rutgeerts, P.; Hanauer, S.; Colombel, J.; Sands, B.; Lukas, M.; Fedorak, R.; Lee, S.; Bressler, B.; Fox, I.; Rosario, M.; Sankoh, S.; Xu, J.; Stephens, K.; Milch, C.; Parikh, A.; and Study Group, GEMINI 2, 'GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease' (2013). Aurora Gastroenterology Fellows. 14.
https://institutionalrepository.aah.org/gastrofellows/14

Abstract

BACKGROUND: The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown.METHODS: In an integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) in adults with active Crohn's disease. In the induction trial, 368 patients were randomly assigned to receive vedolizumab or placebo at weeks 0 and 2 (cohort 1), and 747 patients received open-label vedolizumab at weeks 0 and 2 (cohort 2); disease status was assessed at week 6. In the maintenance trial, 461 patients who had had a response to vedolizumab were randomly assigned to receive placebo or vedolizumab every 8 or 4 weeks until week 52.RESULTS: At week 6, a total of 14.5% of the patients in cohort 1 who received vedolizumab and 6.8% who received placebo were in clinical remission (i.e., had a score on the Crohn's Disease Activity Index [CDAI] of ≤150, with scores ranging from 0 to approximately 600 and higher scores indicating greater disease activity) (P=0.02); a total of 31.4% and 25.7% of the patients, respectively, had a CDAI-100 response (≥100-point decrease in the CDAI score) (P=0.23). Among patients in cohorts 1 and 2 who had a response to induction therapy, 39.0% and 36.4% of those assigned to vedolizumab every 8 weeks and every 4 weeks, respectively, were in clinical remission at week 52, as compared with 21.6% assigned to placebo (P<0.001 and P=0.004 for the two vedolizumab groups, respectively, vs. placebo). Antibodies against vedolizumab developed in 4.0% of the patients. Nasopharyngitis occurred more frequently, and headache and abdominal pain less frequently, in patients receiving vedolizumab than in patients receiving placebo. Vedolizumab, as compared with placebo, was associated with a higher rate of serious adverse events (24.4% vs. 15.3%), infections (44.1% vs. 40.2%), and serious infections (5.5% vs. 3.0%).CONCLUSIONS: Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolizumab (rather than switching to placebo) were more likely to be in remission at week 52. Adverse events were more common with vedolizumab. (Funded by Millennium Pharmaceuticals; GEMINI 2 ClinicalTrials.gov number, NCT00783692.).Comment in Inhibition of leukocyte trafficking in inflammatory bowel disease. [N Engl J Med. 2013]

Document Type

Article

DOI

10.1056/NEJMoa1215739

Gemini 2 5 0 4 Speed

DOWNLOADS

Gemini 2 5 0 4 0 2n

Since October 11, 2017

Gemini 2 5 0 4 Mg